What is EXT608 studying for hypoparathyroidism?

EXT608 is being studied to understand its safety, tolerability, and how it affects calcium levels in adults with hypoparathyroidism. This trial, sponsored by Extend Biosciences Inc., aims to evaluate if this modified hormone attached to vitamin D can help manage this condition. Participants will receive injections and be closely monitored during the study.

Who may be eligible for this hypoparathyroidism clinical trial?

Adults aged 18 to 65 with a confirmed diagnosis of hypoparathyroidism for at least 12 months may be eligible. Both men and women can participate, but women of childbearing potential must use effective birth control. Participants should meet specific calcium and vitamin D levels and not have certain heart, kidney, or gastrointestinal conditions. Please review eligibility criteria for more details.

Is there any cost to participate in this hypoparathyroidism clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. However, personal travel or other expenses may vary and are not guaranteed to be covered. Participants should consider these potential costs when deciding to join.

Actively Recruiting

Phase 2

Age: 18Years - 65Years

All Genders

ID06988670

Phase 2 Study of Weekly EXT608 Injections for Adults Aged 18-65 With Hypoparathyroidism Evaluating Safety, Tolerability, and Effectiveness Compared to Placebo

Led by Extend Biosciences Inc. · Updated on 2025-05-25

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of EXT608 in adults with hypoparathyroidism, a condition characterized by low parathyroid hormone levels affecting calcium balance. This Phase 2, multicenter, randomized, double-blind, placebo-controlled trial aims to better understand how this modified parathyroid hormone attached to vitamin D may work in this population. The study is sponsored by Extend Biosciences Inc. and focuses on adults aged 18 to 65 years who have had hypoparathyroidism for at least 12 months. Participants will receive either EXT608 or a placebo via subcutaneous injection once a week. The trial includes a multiple ascending dose phase, starting with a 50 microgram dose for 4 weeks, followed by individualized dosing for another 8 weeks. The placebo group will receive fixed doses for 4 weeks, then variable doses for 8 weeks. This dosing schedule allows researchers to assess the medications effects at different dose levels and monitor participants closely. During the 12-week treatment period, participants will be monitored for safety and tolerability through tracking of adverse events and laboratory tests. Researchers will also assess pharmacokinetics, serum calcium levels, and calcium supplementation needs. Participants will be asked to comply with study procedures, including using a smartphone diary to record medication doses and symptoms. The trial includes detailed evaluation of laboratory results and clinical outcomes to better understand the impact of EXT608 for hypoparathyroidism.

CONDITIONS

Brief Title

A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

Who Can Participate

Age: 18Years - 65Years

All Genders

Eligibility Criteria

You may qualify if you...

Ability to personally provide written, signed, and dated informed consent.
Willingness and ability to fully comply with study procedures and restrictions.
Male or female aged between 18 and 65 years.
Male participants with female partners of childbearing potential must agree to use barrier contraception or abstain from intercourse during the study period.
Female participants must be surgically sterile, postmenopausal, or use effective birth control if of childbearing potential.
History of hypoparathyroidism for at least 12 months with low PTH and serum calcium below 9 mg/dL.
Treated with daily elemental calcium above specified doses depending on calcitriol use.
Normal blood levels of 25-hydroxyvitamin D within specified range.
Normal thyroid test results for at least 3 months on stable medication or none.
Body mass index under 35 kg/m2.
Albumin-adjusted serum calcium between lower half and middle of normal range at randomization.

You will not qualify if you...

Hypoparathyroidism due to calcium sensing receptor mutation, pseudohypoparathyroidism, other diseases affecting calcium or phosphate metabolism, or requiring parenteral calcium infusions.
Unwillingness to use a smartphone diary daily for recording medication and symptoms.
History of neoplasia except thyroid cancer without recurrence for 5 years.
History or active gastrointestinal diseases affecting calcium absorption.
Severe hypocalcemia causing seizures or cardiac arrhythmias within 6 months prior to screening.
Chronic kidney disease with low eGFR or active kidney stones needing recent pain medication.
Recent use of specific medications including proton pump inhibitors, bisphosphonates, parathyroid hormone analogs, thiazide diuretics, or calcitonin within defined timeframes.
Increased cardiovascular proarrhythmic risk including abnormal QTcF or PR intervals, history of risk factors, or use of QT/QTc prolonging drugs.
Chronic or severe cardiac disease including heart failure, unstable angina, arrhythmias, bradycardia, or hypotension.
Any condition or disease that may interfere with participation or confound study results as judged by the investigator.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here